Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr-Jun;8(2):98-105.
doi: 10.4103/0975-7406.171690.

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

Obamiro Kehinde  1 , Rotimi Kunle  2
Affiliations
Review

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

Obamiro Kehinde et al. J Pharm Bioallied Sci. 2016 Apr-Jun.

Abstract

Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug that has been recently approved to provide further risk reduction. The results of two Phase III trials (thrombin receptor antagonists for clinical event reduction and the TRA 2°P-TIMI 50) have showed that vorapaxar, in addition to standard of care therapy, has the potential to provide further risk reduction in patients with prior MI. A search was made on PubMed on articles related to clinical trials and clinical consideration with the use of vorapaxar. This review article summarizes the results of Phase II trials, Phase III trials, subgroup analysis, precautions, and drug interaction with the use of vorapaxar.

Keywords: Antiplatelet; cardiovascular event; myocardial infarction; vorapaxar.

PubMed Disclaimer

Figures

None
Flowchart of selection process
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Notara V, Panagiotakos DB, Pitsavos CE. Secondary prevention of acute coronary syndrome. Socio-economic and lifestyle determinants: A literature review. Cent Eur J Public Health. 2014;22:175–82. - PubMed
    1. Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, et al. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail. 2011;13:148–53. - PubMed
    1. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81–106. - PMC - PubMed
    1. Jones K, Saxon L, Cunningham W, Adams P Guideline Development Group. Secondary prevention for patients after a myocardial infarction: Summary of updated NICE guidance. BMJ. 2013;347:f6544. - PubMed
    1. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, et al. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study) Eur Heart J. 2010;31:2755–64. - PubMed